Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A registrational bioequivalence study of APL 130227 (sublingual apomorphine) for Parkinson's disease.

X
Trial Profile

A registrational bioequivalence study of APL 130227 (sublingual apomorphine) for Parkinson's disease.

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 04 Jan 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apomorphine (Primary) ; Apomorphine (Primary)
  • Indications Parkinson's disease
  • Focus Pharmacokinetics; Registrational
  • Most Recent Events

    • 21 Oct 2016 This trial was planned by Cynapsus Therapeutics . The Company has now been acquired by Sunovion Pharmaceuticals , according to a Sunovion Pharmaceuticals media release.
    • 04 Apr 2016 According to Cynapsus media release, company plans to file NDA with the FDA near the end of 2016 or in early 2017.
    • 26 Apr 2013 Planned End Date changed from 1 Sep 2013 to 1 Mar 2014, as reported in a Cynapsus Therapeutics media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top